세계의 결핵성 수막염 치료 시장 보고서(2025년)

Tuberculous meningitis treatment refers to the medical approach utilized to manage meningitis caused by the infection of Mycobacterium tuberculosis in the membranes that encase the brain and spinal cord. This treatment generally requires a long-term regimen involving multiple anti-tuberculosis medications, along with supportive therapies and, in some cases, corticosteroids to minimize inflammation and mitigate complications.

The primary treatment modalities for tuberculous meningitis include antibiotic therapy, adjunctive corticosteroid therapy, and neurosurgical interventions. Antibiotic therapy involves the administration of drugs that either eliminate or inhibit the growth of bacteria responsible for the infection. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, catering to various end users such as hospitals, specialty clinics, and other healthcare facilities.

The tuberculous meningitis treatment market size has grown rapidly in recent years. It will grow from $169.67 billion in 2024 to $187.95 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. This growth during the historical period can be attributed to the widespread prevalence of tuberculosis, the surge in HIV/AIDS cases, supportive governmental measures to combat TB, heightened awareness among healthcare professionals, and deficiencies in medical infrastructure.

The tuberculous meningitis treatment market size is expected to see rapid growth in the next few years. It will grow to $279.39 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The projected growth is driven by the increasing occurrence of drug-resistant and extensively drug-resistant forms of TBM, advancements in pediatric formulations, increased funding from governments and international health organizations, and expanding efforts in public education and early detection. Prominent trends anticipated in the forecast period include the adoption of digital health solutions and telemedicine, emergence of new anti-TB medications and supportive therapies, integration of TBM care with HIV treatment programs, improvements in diagnostic technologies for quicker and more accurate results, and innovations in combination treatment strategies.

The increasing prevalence of meningitis is expected to drive the growth of the tuberculous meningitis treatment market. Meningitis, an inflammation of the protective membranes surrounding the brain and spinal cord, is typically caused by infections and can result in severe neurological complications requiring immediate medical care. Antimicrobial resistance is contributing to the rising prevalence of meningitis, making bacterial infections harder to treat, which leads to prolonged illness, higher transmission rates, and an elevated risk of outbreaks. Tuberculous meningitis treatment plays a critical role in managing the disease by eradicating tuberculosis bacteria, reducing inflammation in the brain, and relieving intracranial pressure to prevent complications and support patient recovery. For example, in September 2024, Meningitis Now, a UK-based meningitis charity, reported 396 confirmed cases of invasive meningococcal disease in 2023, an increase from 205 cases in 2022. As a result, the rising prevalence of meningitis is fueling the demand for tuberculous meningitis treatments.

The growth of the tuberculous meningitis treatment market is also supported by increasing healthcare expenditure. Healthcare expenditure refers to the total spending on medical services, treatments, and health-related resources within a specific timeframe. The aging global population is a major factor driving higher healthcare costs, as older individuals typically require more medical services, long-term care, and treatments for age-related conditions, putting added pressure on healthcare systems. Increased healthcare spending supports the treatment of tuberculous meningitis by enabling better diagnostics, advanced drug therapies, professional care, and research and development, all of which contribute to improved patient outcomes. For instance, in April 2025, the American Medical Association reported that healthcare spending in the U.S. grew by 7.5% in 2023, reaching $4.9 trillion or $14,570 per person, which is a notable rise compared to the 4.6% increase recorded in 2022. This growing investment in healthcare is enhancing the development and accessibility of tuberculous meningitis treatments.

Leading companies in the tuberculous meningitis treatment market are focusing on advancing therapeutic options through clinical trials to improve treatment efficacy and patient outcomes. Clinical trials are research studies conducted on humans to determine the safety, effectiveness, and optimal use of medical treatments such as drugs, vaccines, or procedures. These studies are vital for assessing how new treatments perform, identifying potential side effects, and comparing them to existing options before they are approved for broader use. For instance, in December 2023, the AIDS Clinical Trials Group, a U.S.-based organization specializing in HIV clinical research, initiated the IMAGINE-TBM (A5384) clinical trial. This international, randomized, open-label phase 2 study is testing a new six-month treatment regimen for tuberculous meningitis consisting of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide. The new regimen is being compared to the current standard nine-month therapy. The trial, involving 330 participants aged 15 and older from several high-TB-burden countries, aims to assess the safety and effectiveness of the shorter regimen to improve outcomes and reduce the duration of treatment for this serious condition.

Major players in the tuberculous meningitis treatment market are Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Cipla Limited, Cadila Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Lupin Limited, Alkem Laboratories Limited, Macleods Pharmaceuticals Ltd., Torrent Pharmaceuticals Limited, Strides Pharma Science Limited, Ajanta Pharma Limited, Wockhardt Limited, Orchid Pharma Limited, Panacea Biotec Limited, Anuh Pharma Ltd., Rusan Pharma Ltd.

Asia-Pacific was the largest region in the tuberculous meningitis treatment market in 2024. The regions covered in tuberculous meningitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tuberculous meningitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tuberculous meningitis treatment market includes revenues earned by entities by providing services such as, intravenous fluid management, nutritional support, hospitalization and critical care, management of intracranial pressure, and follow-up and rehabilitation services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tuberculous Meningitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tuberculous meningitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tuberculous meningitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tuberculous meningitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Antibiotic Therapy; Adjunctive Corticosteroid Therapy; Neurosurgical Management
• 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 3) By End User: Hospitals; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Antibiotic Therapy: First-Line Anti-Tuberculosis Drugs; Second-Line Anti-Tuberculosis Drugs
• 2) By Adjunctive Corticosteroid Therapy: Dexamethasone; Prednisolone
• 3) By Neurosurgical Management: Ventriculoperitoneal Shunt; External Ventricular Drainage (EVD); Surgical Removal Of Tuberculoma
• Companies Mentioned: Merck & Co. Inc.; Sanofi S.A.; GlaxoSmithKline plc; Otsuka Pharmaceutical Co. Ltd.; Sun Pharmaceutical Industries Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tuberculous Meningitis Treatment Market Characteristics

3. Tuberculous Meningitis Treatment Market Trends And Strategies

4. Tuberculous Meningitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Tuberculous Meningitis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tuberculous Meningitis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tuberculous Meningitis Treatment Market Growth Rate Analysis
• 5.4. Global Tuberculous Meningitis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tuberculous Meningitis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tuberculous Meningitis Treatment Total Addressable Market (TAM)

6. Tuberculous Meningitis Treatment Market Segmentation

• 6.1. Global Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotic Therapy
• Adjunctive Corticosteroid Therapy
• Neurosurgical Management
• 6.2. Global Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.3. Global Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End Users
• 6.4. Global Tuberculous Meningitis Treatment Market, Sub-Segmentation Of Antibiotic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First-Line Anti-Tuberculosis Drugs
• Second-Line Anti-Tuberculosis Drugs
• 6.5. Global Tuberculous Meningitis Treatment Market, Sub-Segmentation Of Adjunctive Corticosteroid Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dexamethasone
• Prednisolone
• 6.6. Global Tuberculous Meningitis Treatment Market, Sub-Segmentation Of Neurosurgical Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ventriculoperitoneal Shunt
• External Ventricular Drainage (EVD)
• Surgical Removal Of Tuberculoma

7. Tuberculous Meningitis Treatment Market Regional And Country Analysis

• 7.1. Global Tuberculous Meningitis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tuberculous Meningitis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tuberculous Meningitis Treatment Market

• 8.1. Asia-Pacific Tuberculous Meningitis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tuberculous Meningitis Treatment Market

• 9.1. China Tuberculous Meningitis Treatment Market Overview
• 9.2. China Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tuberculous Meningitis Treatment Market

• 10.1. India Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tuberculous Meningitis Treatment Market

• 11.1. Japan Tuberculous Meningitis Treatment Market Overview
• 11.2. Japan Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tuberculous Meningitis Treatment Market

• 12.1. Australia Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tuberculous Meningitis Treatment Market

• 13.1. Indonesia Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tuberculous Meningitis Treatment Market

• 14.1. South Korea Tuberculous Meningitis Treatment Market Overview
• 14.2. South Korea Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tuberculous Meningitis Treatment Market

• 15.1. Western Europe Tuberculous Meningitis Treatment Market Overview
• 15.2. Western Europe Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tuberculous Meningitis Treatment Market

• 16.1. UK Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tuberculous Meningitis Treatment Market

• 17.1. Germany Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tuberculous Meningitis Treatment Market

• 18.1. France Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tuberculous Meningitis Treatment Market

• 19.1. Italy Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tuberculous Meningitis Treatment Market

• 20.1. Spain Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tuberculous Meningitis Treatment Market

• 21.1. Eastern Europe Tuberculous Meningitis Treatment Market Overview
• 21.2. Eastern Europe Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tuberculous Meningitis Treatment Market

• 22.1. Russia Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tuberculous Meningitis Treatment Market

• 23.1. North America Tuberculous Meningitis Treatment Market Overview
• 23.2. North America Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tuberculous Meningitis Treatment Market

• 24.1. USA Tuberculous Meningitis Treatment Market Overview
• 24.2. USA Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tuberculous Meningitis Treatment Market

• 25.1. Canada Tuberculous Meningitis Treatment Market Overview
• 25.2. Canada Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tuberculous Meningitis Treatment Market

• 26.1. South America Tuberculous Meningitis Treatment Market Overview
• 26.2. South America Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tuberculous Meningitis Treatment Market

• 27.1. Brazil Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tuberculous Meningitis Treatment Market

• 28.1. Middle East Tuberculous Meningitis Treatment Market Overview
• 28.2. Middle East Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tuberculous Meningitis Treatment Market

• 29.1. Africa Tuberculous Meningitis Treatment Market Overview
• 29.2. Africa Tuberculous Meningitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tuberculous Meningitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tuberculous Meningitis Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tuberculous Meningitis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Tuberculous Meningitis Treatment Market Competitive Landscape
• 30.2. Tuberculous Meningitis Treatment Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis

31. Tuberculous Meningitis Treatment Market Other Major And Innovative Companies

• 31.1. Aurobindo Pharma Limited
• 31.2. Cipla Limited
• 31.3. Cadila Pharmaceuticals Ltd.
• 31.4. Amneal Pharmaceuticals Inc.
• 31.5. Lupin Limited
• 31.6. Alkem Laboratories Limited
• 31.7. Macleods Pharmaceuticals Ltd.
• 31.8. Torrent Pharmaceuticals Limited
• 31.9. Strides Pharma Science Limited
• 31.10. Ajanta Pharma Limited
• 31.11. Wockhardt Limited
• 31.12. Orchid Pharma Limited
• 31.13. Panacea Biotec Limited
• 31.14. Anuh Pharma Ltd.
• 31.15. Rusan Pharma Ltd.

32. Global Tuberculous Meningitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tuberculous Meningitis Treatment Market

34. Recent Developments In The Tuberculous Meningitis Treatment Market

35. Tuberculous Meningitis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Tuberculous Meningitis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tuberculous Meningitis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tuberculous Meningitis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer